LDS/Medical Tests/SMAD2 Gene Mutation Analysis

SMAD2 Gene Mutation Analysis

The SMAD2 gene is located on the long (q) arm of chromosome 18 at position 21.1 and encodes SMAD2 protein. This protein is similar to the Drosophila gene product ‘Mothers against decapentaplegic homolog 2’ and the C. elegans protein SMA. SMAD proteins are signal transducers and transcriptional modulators that mediate multiple signaling pathways. The SMAD2 protein mediates the signaling of transforming growth factor (TGF)-beta, and thus regulates cellular proliferation, apoptosis, and differentiation. Binding of TGFβ to extracellular receptors triggers phosphorylation of SMAD2 at a serine-serine-methionine-serine (SSMS) motif at its extreme C-terminus. Phosphorylated SMAD2 is then able to form a complex with SMAD4. These complexes accumulate in the cell nucleus, where they directly participate in the regulation of gene expression. Mutation in SMAD2 gene is associated with Loeys-Dietz syndrome, Heterotaxy syndrome and some cancers (e.g. colorectal cancer).

Loeys-Dietz syndrome (LDS) is an autosomal dominant disorder that affects many parts of the body. Mutation of the SMAD2 gene has been found in 1-5% of LDS. Mutations that cause Loeys-Dietz syndrome are typically missense mutations in the TGF-β receptor type 1, resulting in a receptor with little or no function. Major manifestations of LDS associated with SMAD2 mutations include cleft palate/bifid uvula, wide spaced eyes, craniosynostosis, tall stature, arachnodactyly, pectus deformity, club foot, aortic root and other aneurysms, tortuous vessels, bicuspid aortic valve, mitral valve insufficiency, straie and dural ectasia. Individuals with LDS are predisposed to widespread and aggressive arterial aneurysms and pregnancy-related complications including uterine rupture and death. They may also have a strong predisposition for allergic/inflammatory disease including asthma, eczema, and reactions to food or environmental allergens. There is also an increased incidence of gastrointestinal inflammation including eosinophilic esophagitis and gastritis or inflammatory bowel disease.

  • Diagnostic confirmation of Loeys-Dietz syndrome (LDS)
  • Risk assessment of asymptomatic family members of a proband with Loeys-Dietz syndrome
  • For predictive testing of at-risk family members
  • Carrier and prenatal screening for families at risk

Positive: Mutation or pathogenic variant in SMAD2 gene. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.

Negative: No mutation or pathogenic variant in SMAD2 gene

Negative for mutation or pathogenic variant in SMAD2 gene

Sequence analysis by next generation sequencing or bi-directional sequencing. SMAD2 gene -targeted deletion/duplication analysis by quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.

Whole blood (EDTA), amniotic fluid (prenatal test).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: Unacceptable
Cardiac panel, TGFBR1, TGFBR2, FBN1, ACTA2 and MYH11 mutation analysis for aortic aneurysms and aortic dissections, Comprehensive Skeletal Dysplasias and Disorders Panel, Ehlers-Danlos Syndrome Panel, Marfan Syndrome Panel.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login